GenSight Biologics gets early access nod for candidate gene therapy in Israel
Applications include detailed scientific rationale and supporting clinical evidence
Applications include detailed scientific rationale and supporting clinical evidence
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Full approval will depend on verification of clinical benefit in a confirmatory trial
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The study met its primary endpoint and all 11 secondary efficacy endpoints
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated